Erratum to “Sustained ERK inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy” [Biochim. Biophys. Acta 1830 (2013) 2659–2670]

Biochimica et Biophysica Acta 1830 (2013) 4417

Contents lists available at SciVerse ScienceDirect

Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbagen

Erratum

Erratum to “Sustained ERK inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy” [Biochim. Biophys. Acta 1830 (2013) 2659–2670] Anette Weyergang a,⁎, Pål K. Selbo a, b, Kristian Berg a a b

Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital Montebello, N-0310 Oslo, Norway PCI Biotech, Strandveien 55, N-1366 Lysaker Norway

In the title, EKR should be listed as ERK. The correct title appears above.

DOI of original article: http://dx.doi.org/10.1016/j.bbagen.2012.11.010. ⁎ Corresponding author. E-mail address: [email protected] (A. Weyergang). 0304-4165/$ – see front matter © 2013 Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.bbagen.2013.05.002